Psychiatry - November 2008 - (Page 36)

ACKNOWLEDGMENT The authors are grateful to Hai-An Hsu, PhD, of Forest Research Institute, who performed the statistical calculations and to Michael L. Miller, PhD, and Vojislav Pejovi´c, PhD, of Prescott Medical Communications Group, who provided data verification and editorial assistance. 12. 13. 14. 15. REFERENCES 1. Aricept®. US Prescribing Information. New York, NY: Pfizer, 2006:November. Birks J, Harvey RJ. Donepezil for dementia due to Alzheimer’s disease. Cochrane Database Syst Rev. 2006(1):CD001190. Razadyne ER. US Prescribing Information. Titusville, NJ: OrthoMcNeil Neurologics, 2007:April. Loy C, Schneider L. Galantamine for Alzheimer’s disease and mild cognitive impairment. Cochrane Database Syst Rev. 2006(1):CD001747. Exelon®. US Prescribing Information. East Hanover, NJ: Novartis, 2006. Exelon Patch®. US Prescribing Information. East Hanover, NJ: Novartis, 2007:July. Birks J, Grimley Evans J, Iakovidou V, et al. Rivastigmine for Alzheimer’s disease. Cochrane Database Syst Rev. 2000(4):CD001191. Black SE, Doody R, Li H, McRae T, et al. Donepezil preserves cognition and global function in patients with severe alzheimer disease. Neurology. 2007;31;69(5):459–469. Feldman H, Gauthier S, Hecker J, et al. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s disease. Neurology. 2001;57(4):613–620. Winblad B, Kilander L, Eriksson S, et al. Donepezil in patients with severe Alzheimer’s disease: doubleblind, parallel-group, placebocontrolled study. Lancet. 2006;367(9516):1057–1065. Seltzer B. Donepezil: an update. Expert Opin Pharmacother. Psychiatry 2008 [ N O V E M B E R ] 2. 3. 16. 4. 17. 5. 6. 18. 7. 19. 8. 20. 21. 9. 22. 10. 23. 11. 24. 2007;8(7):1011–1023. Namenda®. US Prescribing Information. St. Louis, MO: Forest Pharmaceuticals, Inc., 2007:April. McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. Cochrane Database Syst Rev. 2006(2):CD003154. Cummings JL. Alzheimer’s disease. N Engl J Med. 2004;351(1):56–67. Parsons CG. Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system—too little activation is bad, too much is even worse. Neuropharmacology. 2007;53(6):699–723. Epub 2007 Aug 10. Pitkala KH, Laurila JV, Strandberg TE, et al. Behavioral symptoms and the administration of psychotropic drugs to aged patients with dementia in nursing homes and in acute geriatric wards. Int Psychogeriatr. 2004;16(1):61–74. Lacro JP, Jeste DV. Physical comorbidity and polypharmacy in older psychiatric patients. Biol Psychiatry. 1994;36(3):146–152. Namenda®. US Prescribing Information. http://www.frx.com/pi/namenda_pi. pdf. Accessed September, 2007. Aricept®. US Prescribing Information. http://www.aricept.com/PI.html. Accessed September, 2007. Exelon®. US Prescribing Information. http://www.pharma.us.novartis.com /product/pi/pdf/exelon.pdf. Accessed September, 2007. Exelon Patch®. US Prescribing Information. http://www.pharma.us.novartis.com /product/pi/pdf/exelonpatch.pdf. Accessed September, 2007. Razadyne ER. US Prescribing Information. http://razadyneer.com/razadyneer/p ages/pdf/razadyne_er.pdf. Accessed September, 2007. Bland JM, Altman DG. Statistics notes. The odds ratio. BMJ. 2000;320(7247):1468. Birks J. Cholinesterase inhibitors for Alzheimer’s disease. Cochrane 25. 26. 27. 28. 29. Database Syst Rev. 2006(1):CD005593. Anand R, Hartman R, Sohn H, et al. Impact of study design and patient population on outcomes from cholinesterase inhibitor trials. Am J Geriatr Psychiatry. Mar-Apr 2003;11(2):160–168. Winblad B, Grossberg G, Frolich L, et al. IDEAL: a 6-month, doubleblind, placebo-controlled study of the first skin patch for Alzheimer disease. Neurology. 2007;69(4 Suppl 1):S14–22. Winblad B, Kawata AK, Beusterien KM, et al. Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer’s disease. Int J Geriatr Psychiatry. 2007;22(5):485–491. Winblad B, Cummings J, Andreasen N, et al. A six-month double-blind, randomized, placebocontrolled study of a transdermal patch in Alzheimer’s disease— rivastigmine patch versus capsule. Int J Geriatr Psychiatry. 2007;22(5):456–467. Tariot PN, Farlow MR, Grossberg GT, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA. 2004;291(3):317–324. 36 http://www.frx.com/pi/namenda_pi.pdf http://www.frx.com/pi/namenda_pi.pdf http://www.aricept.com/PI.html http://www.pharma.us.novartis.com/product/pi/pdf/exelon.pdf http://www.pharma.us.novartis.com/product/pi/pdf/exelonpatch.pdf http://razadyneer.com/razadyneer/pages/pdf/razadyne_er.pdf http://razadyneer.com/razadyneer/pages/pdf/razadyne_er.pdf

Table of Contents Feed for the Digital Edition of Psychiatry - November 2008

Psychiatry - November 2008 Editor's Message Editorial Advisory Board Contents PsychRx Letters to the Editor Measuring Adverse Events in Psychiatry Nonsuicidal Self Injury in Adolescents Relative Tolerability of Alzheimer's Disease Treatments Biracial Identity Development and Recommendations in Therapy Depression and Cardiovascular Disease: Just an Urban Legend? Three Risk Management Basics Journal Watch Classified Advertising Information for Authors

Psychiatry - November 2008

For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.